R&D Trends

Boehringer Ingelheim, China Southeast University collaborate

Tuesday, November 29, 2016

Boehringer Ingelheim and China Southeast University Institute of Life Sciences have announced the start of a joint research project to develop new treatment approaches for hearing loss through regeneration of hair cells from inner ear stem cells. The new collaboration combines the expertise of Professor Renjie Chai, one of the worldwide leaders in the field of hearing loss, with Boehringer Ingelheim’s expertise in drug discovery and clinical development to pave the way for the development of much needed new treatment options for this condition.

[Read More]

MYnd Analytics, Carolina Partners to launch personalized mental health program

Monday, November 21, 2016

MYnd Analytics and Carolina Partners in Mental Healthcare are teaming up to provide personalized care to veterans and civilians seeking quality evidence based mental health care. Carolina Partners, a 25 clinic outpatient psychiatry group practice based in Durham, N.C., is the first non-governmental site to launch the SMART-MD protocol for Veterans. This randomized, double-blind, multi-site clinical study will enroll patients—including veterans, active service members and their families—with a primary diagnosis of depression. 

[Read More]

Bristol-Myers Squibb, Enterome form immuno-oncology collaboration

Monday, November 21, 2016

Bristol-Myers Squibb and Enterome, a developer of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Additionally, the collaboration will seek to identify novel microbiome-derived biomarkers in an effort to improve clinical outcomes for patients treated with Bristol-Myers Squibb’s Immuno-Oncology portfolio.

[Read More]

Da Volterra, The Medicines Company join COMBACTE-NET to combat antimicrobial resistance

Friday, November 18, 2016

The Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) project COMBACTE-NET announces that two new pharmaceutical companies, Da Volterra and The Medicines Company, have joined the project as partners. Together with the existing partners the new partners will closely collaborate to further strengthen the public-private partnership aiming to combat the worldwide growing problem of antimicrobial resistance.

[Read More]

Roche launches global cancer immunotherapy network imCORE

Friday, November 18, 2016

Roche has launched the global cancer immunotherapy Centers of Research Excellence (imCORE) Network. This network brings together many of the world’s leading scientific and clinical experts in cancer immunotherapy to collaborate in investigating the most promising new treatment approaches. The goal is to rapidly initiate pre-clinical and clinical research based on the latest scientific discoveries and to aggregate and share data to accelerate the search for cures for people with cancer. The imCORE Network will focus on identifying approaches to expand the number of people who benefit from cancer immunotherapy by exploring new ways to activate a person’s immune system to fight their cancer.

[Read More]

Curable initiates the International PSC Genome Project

Friday, November 18, 2016

Curable, a nonprofit research accelerator that applies engineering approaches to medicine to develop solutions for rare diseases, has announced the initiation of the International PSC Genome Project, which includes the Regeneron Genetics Center (RGC, a wholly-owned subsidiary of Regeneron Pharmaceuticals) and the Mayo Clinic with the goal of conducting the largest sequencing project for primary sclerosing cholangitis (PSC) to date.

[Read More]